Low dose combination steroids control autoimmune mouse hearing loss.

Area of Science:

• Otolaryngology
• Immunology
• Pharmacology

Background:

• Severe side effects of glucocorticoids limit long-term hearing loss management.
• Alternative steroid therapies are needed to reduce adverse effects in hearing disorder treatment.

Purpose of the Study:

• To evaluate the efficacy of combining low-dose aldosterone and prednisolone for autoimmune hearing loss in mice.
• To assess the effectiveness of low-dose fludrocortisone in managing autoimmune hearing loss.

Main Methods:

• MRL/MpJ-Fas(lpr) mice were used to model autoimmune hearing loss.
• Mice were treated with varying doses of aldosterone, prednisolone, or a combination, and fludrocortisone.
• Auditory Brainstem Response (ABR) thresholds were measured to assess hearing function before and after treatment.

Main Results:

• Neither prednisolone nor aldosterone alone prevented hearing loss at tested doses.
• Combined low-dose aldosterone and prednisolone effectively controlled autoimmune hearing loss.
• Low doses of fludrocortisone also demonstrated efficacy in preventing or reversing hearing loss.

Conclusions:

• Combined low-dose steroid therapy shows promise for managing autoimmune hearing loss.
• This approach may reduce the side effects associated with traditional glucocorticoid treatments.
• Fludrocortisone presents a viable alternative for treating hearing disorders.